Management of Alzheimer's disease: Defining the role of donepezil

Disease Management and Health Outcomes

Volumn 10, Issue 1, 2002, Pages 41-54

  Ibbotson, Tim ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ALKALOID DERIVATIVE; AMINOACRIDINE DERIVATIVE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PHENANTHRENE DERIVATIVE; PIPERIDINE DERIVATIVE; RIVASTIGMINE; TACRINE;

ALGORITHM; ALZHEIMER DISEASE; COGNITIVE DEFECT; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; INSOMNIA; INSTITUTIONALIZATION; NAUSEA; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; UNITED STATES; VERTIGO; VOMITING;

EID: 0036179692     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200210010-00004     Document Type: Review

References (73)

1. Donepezil: A review of its use in Alzheimer's disease
2. NICE issues guidance on drugs for Alzheimer's disease
3. Pathophysiology of Alzheimer's syndrome
4. Apolipoprotein E episolon-4 and incidence of Alzheimer disease in a community population of older persons
5. Pharmacological treatment of Alzheimer disease: From psychotropic drugs and cholinesterase inhibitors to pharmacogenomics
6. The clinical introduction of genetic testing for Alzheimer disease: An ethical perspective
7. Cholinesterase inhibitors: A new class of psychotropic compounds
8. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives
9. New treatment options in Alzheimer's disease reviewed
10. Alzheimer's disease and its management in the year 2010
11. The pharmacoeconomics of Alzheimer's disease
12. Alzheimer disease. Report of the council on scientific affairs
13. Education and other socioeconomic determinants of dementia and Alzheimers disease
14. Prevalence and risks of dementia in the Japanese population: RERF's adult health study Hiroshima subjects
15. Age-specific incidence rates of Alzheimer's disease: The Baltimore longitudinal study of aging
16. Prevalence and subtypes of dementia in a rural Chinese population
17. Very old women at highest risk of dementia and Alzheimer's disease: Incidence data from the Kungsholmen project, Stockholm
18. Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons
19. Incidence of very mild to severe dementia and Alzheimer's disease in Denmark: The Odense study
20. Prevalence of Alzheimer's disease and other dementias in rural India: The Indo-US study
21. Prevalence of dementia in Chinese elderly in Hong Kong
22. The Canadian study of health and aging. Canadian study of health and aging: Study methods and prevalence of dementia
23. Economic considerations in Alzheimer's disease
24. An economic perspective on Alzheimer's disease
25. The economic impact of Alzheimer's disease
26. The US economic and social costs of Alzheimers disease revisited
27. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: A managed care perspective
28. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada
29. Nursing home care for the patient with Alzheimers disease
30. The cost of institutional care in Alzheimer's disease: Nursing home and hospital use in a prospective cohort
31. The burden of caring for Alzheimers disease patients
32. Practice parameter: Management of dementia
33. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II - Pharmacologic therapy
34. Donepezil for the management of patients with Alzheimer's disease: A good choice from among the cholinesterase inhibitors
35. ARICEPT® (donepezil hydrochloride tablets)
36. REMINYL® (galantamine hydrobromide) tablets
37. EXELON® (rivastigmine tartrate) capsules
38. Acetylcholinesterase inhibitors in the treatment of Alzheimer's disease
39. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease
40. Cholinesterase inhibitors for Alzheimer's disease
41. Acetylcholinesterase inhibitors in Alzheimer's disease
42. Rivastigmine: A pharmacoeconomic review of its use in Alzheimer's disease
43. Galantamine for Alzheimer's disease
44. Galantamine: A review of its use in Alzheimer's disease
45. A controlled trial of selegiline, alpha-to-copherol, or both as treatment for Alzheimer's disease
46. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET
47. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
48. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
49. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study
50. Donepezil therapy in clinical practice: A randomized crossover study
51. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
52. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan
53. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
54. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
55. Defining meaningful change in Alzheimer's disease trials: The donepezil experience
56. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
57. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study
58. The Gottfries-Bråne-Steen scale: Validity, reliability and application in antidementia drug trials
59. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
60. Cholinergic markers in elderly patients with early signs of Alzheimer's disease
61. Comparison of the tolerability, ease of use, and efficacy of donepezil and rivastigmine in Alzheimer's disease patients: A 12-week multinational study
62. Donepezil: An anticholinesterase inhibitor for Alzheimer's disease
63. Adverse effects associated with the use of donepezil in general practice in England
64. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease (AD)
65. Donepezil for the treatment of Alzheimer's disease: A multinational clinical experience study
66. Donepezil delays time to nursing home placement in patients with Alzheimer's disease
67. An economic evaluation of donepezil in the treatment of Alzheimer's disease
68. Donepezil use in managed Medicare: Effect on health care costs and utilization
69. Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years' therapy using donepezil
70. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: A Markov model
71. The cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
72. An econonic evaluation of donepezil in mild to moderate Alzheimer's disease patients: Results of a one-year, double-blind, randomized trial